Back to top
more

Chemed (CHE)

(Real Time Quote from BATS)

$583.75 USD

583.75
23,034

+5.98 (1.04%)

Updated Oct 8, 2024 02:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 10% (25 out of 252)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Cardiovascular Systems (CSII) Beats on Q4 Earnings & Revenues

by Zacks Equity Research

Cardiovascular Systems (CSII) sees strength in Coronary device and peripheral device segments in Q4.

    DVA vs. CHE: Which Stock Should Value Investors Buy Now?

    by Zacks Equity Research

    DVA vs. CHE: Which Stock Is the Better Value Option?

      Chemed (CHE) Beats on Q2 Earnings & Revenues, View Raised

      by Zacks Equity Research

      Chemed (CHE) rides on strong contributions from the Roto-Rooter and VITAS businesses in Q2.

        Outpatient & Home Healthcare Stock Outlook: Prospects Bright

        by Zacks Equity Research

        The outpatient and home healthcare companies are raking in huge profits of late, courtesy of AI-based treatment procedures that are easy, pocket friendly and ensure faster recovery.

          Nabaparna Bhattacharya headshot

          Outpatient Market Gains on Social Awareness: 3 Stocks in Focus

          by Nabaparna Bhattacharya

          Here we discuss how Medical Outpatient and home healthcare continue to create opportunities for investors keen on parking their money in the healthcare space.

            LHCG or CHE: Which Is the Better Value Stock Right Now?

            by Zacks Equity Research

            LHCG vs. CHE: Which Stock Is the Better Value Option?

              Walgreens Boots' Retail Pharmacy Strong Despite Several Woes

              by Zacks Equity Research

              Walgreens Boots' (WBA) consistent sales rise in the Retail Pharmacy International business is encouraging. Moreover, the company steadily gains traction from a slew of strategic deals.

                Here's Why You Should Add Amedisys (AMED) to Your Portfolio

                by Zacks Equity Research

                Amedisys' (AMED) solid performance in the recently launched Personal Care segment buoys optimism. A favorable demographic trend and strategic acquisitions also bode well for the company.

                  Tirthankar Chakraborty headshot

                  New Strong Buy Stocks for June 18th

                  by Tirthankar Chakraborty

                  Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday

                    LHCG or CHE: Which Is the Better Value Stock Right Now?

                    by Zacks Equity Research

                    LHCG vs. CHE: Which Stock Is the Better Value Option?

                      Envision Healthcare's (EVHC) Ratings on Review for Downgrade

                      by Zacks Equity Research

                      Moody's Investor Service puts Envision Healthcare's (EVHC) ratings and outlook on review for downgrade.

                        The Zacks Analyst Blog Highlights: Oshkosh, Chemed and Urban Outfitters

                        by Zacks Equity Research

                        The Zacks Analyst Blog Highlights: Oshkosh, Chemed and Urban Outfitters

                          John Blank headshot

                          The World Cup Begins: Global Week Ahead

                          by John Blank

                          We have lots of global events this week, counted in terms of soccer games, a historic diplomatic summit, and three major monetary policy meetings.

                            Cooper Companies (COO) Q2 Earnings & Revenues Beat Estimates

                            by Zacks Equity Research

                            Cooper (COO) witnesses strong growth across segments and geographies in fiscal Q2.

                              LHCG or CHE: Which Is the Better Value Stock Right Now?

                              by Zacks Equity Research

                              LHCG vs. CHE: Which Stock Is the Better Value Option?

                                Should Vanguard S&P Small-Cap 600 Growth ETF (VIOG) Be on Your Investing Radar?

                                by Zacks Equity Research

                                Style Box ETF report for VIOG

                                  Why Is Chemed (CHE) Up 13.6% Since Its Last Earnings Report?

                                  by Zacks Equity Research

                                  Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                    Amedisys or Chemed: Which is a Better Investment Choice?

                                    by Zacks Equity Research

                                    After considering various parameters and fundamentals, we help you make a choice between Amedisys (AMED) and Chemed (CHE).

                                      Chemed (CHE) Stock is Worth a Bet Right Now: Here's Why

                                      by Zacks Equity Research

                                      Chemed (CHE) sees a stellar Q1 backed by steady year-over-year revenue growth in both of its subsidiaries.

                                        BioScrip (BIOS) Q1 Loss Wider Than Expected, Revenues Beat

                                        by Zacks Equity Research

                                        BioScrip's (BIOS) shift in strategy to raise core revenue mix hampers growth in Q1. Year-over-year rise in core product mix buoys optimism.

                                          STERIS (STE) Q4 Earnings & Revenues Beat Estimates, Up Y/Y

                                          by Zacks Equity Research

                                          Favorable underlying market trends along with a slew of new product and service offerings by STERIS (STE) instill confidence in investors.

                                            Henry Schein's (HSIC) Q1 Earnings Beat, '18 View Intact

                                            by Zacks Equity Research

                                            We currently await the completion of Henry Schein's (HSIC) planned spin-off of global Animal Health business. This business contributes nearly 30% to the company's top line.

                                              Align Technology (ALGN) Beats on Earnings and Revenues in Q1

                                              by Zacks Equity Research

                                              Align Technology (ALGN) gains on solid contributions from Clear Aligner as well as Scanner and Service segments in Q1.

                                                Becton, Dickinson (BDX) Beats on Q2 Earnings, Lifts '18 View

                                                by Zacks Equity Research

                                                Becton, Dickinson (BDX) gains on solid segmental performance in Q2; a raised guidance for fiscal 2018 encourages.

                                                  Chemed (CHE) Hits a 52-Week High, Can the Run Continue?

                                                  by Zacks Equity Research

                                                  Chemed Corporation is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for CHE for clues.